Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ain Shams University
Files of breast cancer patients attending breast cancer clinic at Ain Shams University Clinical oncology and nuclear medicine department will be viewed by the investigator and those who fit the selection criteria will be included in the study. Tru-cut or core tissue biopsies obtained from the participants for initial diagnosis will be collected and PD-L1 testing will be done on the specimens. Scoring of PD-L1 will be done using Combined positive score (CPS) score. PD-L1 expression will be evaluated among Her-2 positive and triple negative subtypes and will be correlated with pathological complete response after reviewing the postoperative pathology results of the patients.
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Patients aged 18 years old or more
Histologically proven invasive breast cancer
Any T stage, any N Stage with no distant metastasis M0 as evident by clinical examination and sonomammography.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 2.
Patients with Her-2 positive Luminal B subtype, Her-2 enriched or triple negative breast cancer.
Patients who completed their systemic neoadjuvant therapy.
You may not be if
Second malignancy
Patients with early breast cancer clinicallyT1 (≤ 2 cm) N0
Metastatic patients M1
Patients with autoimmune diseases (Type I Diabetes mellitus, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjogren's syndrome and Behcet disease)
Patients on systemic steroids or other immunomodulators (as Methotrexate, Tacrolimus and Cyclosporine)
Patients who started but didn't complete neoadjuvant systemic therapy
Patients who didn't undergo surgery after neoadjuvant systemic therapy
Clareo Health | Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer
